Literature DB >> 24938202

Somatoform disorders and rheumatic diseases: from DSM-IV to DSM-V.

A Alciati1, F Atzeni, P Sgiarovello, P Sarzi-Puttini.   

Abstract

Medically unexplained symptoms are considered 'somatoform disorders' in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The introduction of this nosographic category has been helpful in drawing attention to a previously neglected area, but has not been successful in promoting an understanding of the disorders' biological basis and treatment implications, probably because of a series of diagnostic shortcomings. The newly proposed DSM-V diagnostic criteria try to overcome the limitations of the DSM-IV definition, which was organised centrally around the concept of medically unexplained symptoms, by emphasising the extent to which a patient's thoughts, feelings and behaviours concerning their somatic symptoms are disproportionate or excessive. This change is supported by a growing body of evidence showing that psychological and behavioural features play a major role in causing patient disability and maintaining high level of health care use. Pain disorders is the sub-category of DSM-IV somatoform disorders that most closely resembles fibromyalgia. Regardless of the diagnostic changes recently brought about by DSM-V, neuroimaging studies have identified important components of the mental processes associated with a DSM- IV diagnosis of pain disorder.

Entities:  

Mesh:

Year:  2014        PMID: 24938202     DOI: 10.4081/reumatismo.2014.770

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  2 in total

1.  Does it mean anything to diagnose fibromyalgia (FM) in somebody with chronic widespread pain?

Authors:  Luis Jose Catoggio
Journal:  Clin Rheumatol       Date:  2015-05-29       Impact factor: 2.980

2.  Frequency of mental disorders among chronic pain patients with or without fibromyalgia in Japan.

Authors:  Kenji Miki; Aya Nakae; Kenrin Shi; Yuka Yasuda; Hidenaga Yamamori; Michiko Fujimoto; Manabu Ikeda; Masahiko Shibata; Masao Yukioka; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2018-08-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.